Identification of covalent active site inhibitors of dengue virus protease
Xiaoying Koh-Stenta,1 Joma Joy,1 Si Fang Wang,1 Perlyn Zekui Kwek,1 John Liang Kuan Wee,1 Kah Fei Wan,2 Shovanlal Gayen,1 Angela Shuyi Chen,1 CongBao Kang,1 May Ann Lee,1 Anders Poulsen,1 Subhash G Vasudevan,3 Jeffrey Hill,1 Kassoum Nacro11Experimental Therapeutics Centre, Agency for Science, Techno...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2015-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_c587f1e7c8f24b199445d1bed6b5911a | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Koh-Stenta X |e author |
| 700 | 1 | 0 | |a Joy J |e author |
| 700 | 1 | 0 | |a Wang SF |e author |
| 700 | 1 | 0 | |a Kwek PZ |e author |
| 700 | 1 | 0 | |a Wee JLK |e author |
| 700 | 1 | 0 | |a Wan KF |e author |
| 700 | 1 | 0 | |a Gayen S |e author |
| 700 | 1 | 0 | |a Chen AS |e author |
| 700 | 1 | 0 | |a Kang C |e author |
| 700 | 1 | 0 | |a Lee MA |e author |
| 700 | 1 | 0 | |a Poulsen A |e author |
| 700 | 1 | 0 | |a Vasudevan SG |e author |
| 700 | 1 | 0 | |a Hill J |e author |
| 700 | 1 | 0 | |a Nacro K |e author |
| 245 | 0 | 0 | |a Identification of covalent active site inhibitors of dengue virus protease |
| 260 | |b Dove Medical Press, |c 2015-12-01T00:00:00Z. | ||
| 500 | |a 1177-8881 | ||
| 520 | |a Xiaoying Koh-Stenta,1 Joma Joy,1 Si Fang Wang,1 Perlyn Zekui Kwek,1 John Liang Kuan Wee,1 Kah Fei Wan,2 Shovanlal Gayen,1 Angela Shuyi Chen,1 CongBao Kang,1 May Ann Lee,1 Anders Poulsen,1 Subhash G Vasudevan,3 Jeffrey Hill,1 Kassoum Nacro11Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR), Singapore; 2Novartis Institute for Tropical Diseases, Singapore; 3Program in Emerging Infectious Diseases, Duke-NUS Graduate Medical School, SingaporeAbstract: Dengue virus (DENV) protease is an attractive target for drug development; however, no compounds have reached clinical development to date. In this study, we utilized a potent West Nile virus protease inhibitor of the pyrazole ester derivative class as a chemical starting point for DENV protease drug development. Compound potency and selectivity for DENV protease were improved through structure-guided small molecule optimization, and protease-inhibitor binding interactions were validated biophysically using nuclear magnetic resonance. Our work strongly suggests that this class of compounds inhibits flavivirus protease through targeted covalent modification of active site serine, contrary to an allosteric binding mechanism as previously described.Keywords: flavivirus protease, small molecule optimization, covalent inhibitor, active site binding, pyrazole ester derivatives | ||
| 546 | |a EN | ||
| 690 | |a flavivirus protease | ||
| 690 | |a small molecule optimization | ||
| 690 | |a covalent inhibitor | ||
| 690 | |a active site binding | ||
| 690 | |a pyrazole ester derivatives | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Drug Design, Development and Therapy, Vol 2015, Iss Issue 1, Pp 6389-6399 (2015) | |
| 787 | 0 | |n https://www.dovepress.com/identification-of-covalent-active-site-inhibitors-of-dengue-virus-prot-peer-reviewed-article-DDDT | |
| 787 | 0 | |n https://doaj.org/toc/1177-8881 | |
| 856 | 4 | 1 | |u https://doaj.org/article/c587f1e7c8f24b199445d1bed6b5911a |z Connect to this object online. |